Remove Development Remove FDA Approval Remove In-Vitro
article thumbnail

Top 30 New Medical Devices of 2024

XTalks

From non-invasive cancer diagnostics to life-saving cardiovascular implants, the latest medical devices cleared or approved by the FDA in 2024 reflect the remarkable strides in science and engineering. Date of FDA approval : March 29, 2024 Approved for : To detect exposure to human parvovirus B19.

article thumbnail

US FDA approves Ellipses Pharma’s IND for AML therapy 

Pharmaceutical Technology

The dual FLT-3 and Aurora kinase inhibitor EP0042 is being developed to treat AML patients who have developed FLT3 inhibitor resistance. Ellipses Pharma stated that the dual FLT3 inhibition and Aurora kinase demonstrated to overcome the acquired resistance to selectively inhibit FLT3 in vitro and in vivo.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Imkeldi (Imatinib): Shorla Oncology Adds Another Accessible Solution to Its Leukemia Pipeline

XTalks

Shorla Oncology has received US Food and Drug Administration (FDA) approval for Imkeldi, an oral solution of imatinib designed to treat specific forms of leukemia and other cancers. These cancers affect thousands of patients annually in the US, making Imkeldi’s approval a meaningful step forward in addressing unmet treatment needs.

In-Vivo 105
article thumbnail

Surmodics and Abbott’s Drug-Coated Balloon for Peripheral Artery Disease Gets FDA Approval

XTalks

Medical device and in vitro diagnostics technologies provider SurModic Inc. has announced that its new drug-coated balloon (DCB) SurVeil has been granted approval by the US Food and Drug Administration (FDA). The balloon is designed for the treatment of patients with peripheral artery disease.

article thumbnail

Veklury Becomes the First FDA-Approved COVID-19 Treatment for Children Under 12

XTalks

Gilead’s Veklury (remdesivir) gets FDA approval to treat young children with COVID-19 and becomes the first and only approved COVID-19 treatment for children under 12. This is the only approved COVID-19 treatment for children under 12 years of age. SARS-CoV-2 is known to affect people of all ages.

article thumbnail

Maculus Therapeutix welcomes Privity FZ LLE and Prepares Capital Raise for Novel Drug Delivery Platform

Pharma Mirror

Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Capable of delivering any FDA approved.

article thumbnail

Novo Nordisk moves to strengthen obesity efforts

pharmaphorum

After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics. Central nervous system-controlled behaviour, such as food intake, is notoriously difficult to explore in vitro.